Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	Oliena Studio Stroke and language recovery: 9000+ videos Español • Italiano • Sardu • English | PDF+

Bladder Cancer

Free Subscription 12.08.2019 1 Abdom Radiol (NY) 1 Ann Surg Oncol 1 BJU Int 1 Cancer Cytopathol 1 Cancer Sci 1 Crit Rev Oncol Hematol 1 Dose Response 1 Immunotherapy 1 Int J Cancer 1 Int J Mol Sci 1 Investig Clin Urol 1 J Cancer Res Clin Oncol 1 J Pharm Pharmacol 1 J Urol 1 Nat Rev Urol 1 Oncogene 1 Photodiagnosis Photodyn Ther 15 Transl Androl Urol 1 Turk Patoloji Derg 3 Urol Oncol 1 World J Urol

Retrieve available abstracts of this week’s articles: HTML format Text format

Single Articles

Abdom Radiol (NY)

1. MIRMOMEN SM, Shinagare AB, Williams KE, Silverman SG, et al
   Preoperative imaging for locoregional staging of bladder cancer.
   Abdom Radiol (NY). 2019 Aug 3. pii: 10.1007/s00261-019-02168.
   PubMed     Text format     Abstract available
   
   

   
   Ann Surg Oncol

2. YOSHIDA T, Shida D, Taniguchi H, Tsukamoto S, et al
   Long-Term Outcomes Following Partial Versus Complete Cystectomy in Advanced Colorectal Cancer with Regarding to the Extent of Bladder Invasion.
   Ann Surg Oncol. 2019 Mar 7. pii: 10.1245/s10434-019-07276.
   PubMed     Text format     Abstract available
   
   

   
   BJU Int

3. JUNG A, Nielsen ME, Crandell JL, Palmer MH, et al
   Health-Related Quality of Life among Non-Muscle-Invasive Bladder Cancer Survivors: A Population-Based Study.
   BJU Int. 2019 Aug 5. doi: 10.1111/bju.14888.
   PubMed     Text format     Abstract available
   
   

   
   Cancer Cytopathol

4. DUGAS SG, Muller DC, Le Magnen C, Federer-Gsponer J, et al
   Immunocytochemistry for ARID1A as a potential biomarker in urine cytology of bladder cancer.
   Cancer Cytopathol. 2019 Aug 6. doi: 10.1002/cncy.22167.
   PubMed     Text format     Abstract available
   
   

   
   Cancer Sci

5. MIYAKE M, Hori S, Ohnishi S, Toritsuka M, et al
   Supplementary GM-CSF to chemotherapy and PD-L1 blockade decreases local recurrence after surgery in bladder cancer.
   Cancer Sci. 2019 Aug 5. doi: 10.1111/cas.14158.
   PubMed     Text format     Abstract available
   
   

   
   Crit Rev Oncol Hematol

6. AMESTOY F, Roubaud G, Antoine M, Fonteyne V, et al
   Review of hypo-fractionated radiotherapy for localized muscle invasive bladder cancer.
   Crit Rev Oncol Hematol. 2019;142:76-85.
   PubMed     Text format    
   
   

   
   Dose Response

7. BOFFETTA P, Borron C
   Low-Level Exposure to Arsenic in Drinking Water and Risk of Lung and Bladder Cancer: A Systematic Review and Dose-Response Meta-Analysis.
   Dose Response. 2019;17:1559325819863634.
   PubMed     Text format     Abstract available
   
   

   
   Immunotherapy

8. SHARIAT SF, Enikeev DV, Mostafaei H
   Six essential conditions for bladder-sparing strategies in bacillus Calmette-Guerin unresponsive bladder cancer.
   Immunotherapy. 2019 Aug 6. doi: 10.2217/imt-2019-0083.
   PubMed     Text format    
   
   

   
   Int J Cancer

9. ZHANG K, Dai H, Liang W, Zhang L, et al
   Fermented dairy foods intake and risk of cancer.
   Int J Cancer. 2019;144:2099-2108.
   PubMed     Text format     Abstract available
   
   

   
   Int J Mol Sci

10. HONG SH, Cha HJ, Hwang-Bo H, Kim MY, et al
    Anti-Proliferative and Pro-Apoptotic Effects of Licochalcone A through ROS-Mediated Cell Cycle Arrest and Apoptosis in Human Bladder Cancer Cells.
    Int J Mol Sci. 2019;20.
    PubMed     Text format     Abstract available
    
    

    
    Investig Clin Urol

11. ZUGAIL AS, Pinar U, Irani J
    Evaluation of pain and catheter-related bladder discomfort relative to balloon volumes of indwelling urinary catheters: A prospective study.
    Investig Clin Urol. 2019;60:35-39.
    PubMed     Text format     Abstract available
    
    

    
    J Cancer Res Clin Oncol

12. KIM SJ, You D, Jeong IG, Song C, et al
    Prognosis of carcinoma in situ according to the presence of papillary bladder tumors after bacillus Calmette-Guerin immunotherapy.
    J Cancer Res Clin Oncol. 2019;145:2131-2140.
    PubMed     Text format     Abstract available
    
    

    
    J Pharm Pharmacol

13. MIRANDA MA, Marcato PD, Carvalho IPS, Silva LB, et al
    Assessing the cytotoxic potential of glycoalkaloidic extract in nanoparticles against bladder cancer cells.
    J Pharm Pharmacol. 2019 Aug 5. doi: 10.1111/jphp.13145.
    PubMed     Text format     Abstract available
    
    

    
    J Urol

14. WEI L, Hussein AA, Ma Y, Azabdaftari G, et al
    Accurate Quantification of Residual Cancer Cells in Pelvic Washing Reveals Association with Cancer Recurrence Following Robot-Assisted Radical Cystectomy.
    J Urol. 2019;201:1105-1114.
    PubMed     Text format     Abstract available
    
    

    
    Nat Rev Urol

15. THOMA C
    Combining epigenetic and immune checkpoint inhibitors in bladder cancer.
    Nat Rev Urol. 2019 Aug 6. pii: 10.1038/s41585-019-0221.
    PubMed     Text format    
    
    

    
    Oncogene

16. VANTAKU V, Putluri V, Bader DA, Maity S, et al
    Epigenetic loss of AOX1 expression via EZH2 leads to metabolic deregulations and promotes bladder cancer progression.
    Oncogene. 2019 Aug 5. pii: 10.1038/s41388-019-0902.
    PubMed     Text format     Abstract available
    
    

    
    Photodiagnosis Photodyn Ther

17. CHAN KM, Vasilev K, Shirazi HS, Mcnicholas K, et al
    Biosensor device for the photo-specific detection of immuno-captured bladder cancer cells using hexaminolevulinate: An ex-vivo study.
    Photodiagnosis Photodyn Ther. 2019 Aug 5. pii: S1572-1000(19)30232.
    PubMed     Text format     Abstract available
    
    

    
    Transl Androl Urol

18. BOSSCHIETER J, van Moorselaar RJA, Nieuwenhuijzen JA
    An immediate, single instillation of mitomycin C in non-muscle invasive bladder cancer: can we define which patients do and do not benefit?
    Transl Androl Urol. 2019;8.
    PubMed     Text format    
    
    
19. SHERIF A
    The risk of oversimplification in risk-stratification of neoadjuvant chemotherapy-responses in muscle invasive bladder cancer.
    Transl Androl Urol. 2019;8.
    PubMed     Text format    
    
    
20. LEE SM
    Prognosis in high-grade T1 bladder cancer: host immune response and tumour infiltrating lymphocytes.
    Transl Androl Urol. 2019;8.
    PubMed     Text format    
    
    
21. MIYAKE M, Owari T, Hori S, Fujimoto K, et al
    Significant lack of urine-based biomarkers to replace cystoscopy for the surveillance of non-muscle invasive bladder cancer.
    Transl Androl Urol. 2019;8.
    PubMed     Text format    
    
    
22. KOOL R, Joao Mansure J, Kassouf W
    Molecular subtyping, tumor infiltration, and trimodal therapy for muscle-invasive bladder cancer: more questions than answers.
    Transl Androl Urol. 2019;8.
    PubMed     Text format    
    
    
23. KIM J
    Looking into the clinical application of CD47-targeted near-infrared photoimmunotherapy for human bladder cancer treatment.
    Transl Androl Urol. 2019;8.
    PubMed     Text format    
    
    
24. SINGLA N, Ghandour RA, Raj GV
    Biomarkers for platinum sensitivity in bladder cancer: are we there yet?
    Transl Androl Urol. 2019;8.
    PubMed     Text format    
    
    
25. SOSNOWSKI R, Kamecki H, Bjurlin MA, Przewozniak K, et al
    The diagnosis of bladder cancer: are we missing a teachable moment for smoking cessation?
    Transl Androl Urol. 2019;8.
    PubMed     Text format    
    
    
26. SAID N
    Establishing and characterization of human and murine bladder cancer organoids.
    Transl Androl Urol. 2019;8.
    PubMed     Text format    
    
    
27. DAZA J, Gul Z, Sfakianos JP
    Role of heat shock proteins in bladder cancer: potential biomarkers for treatment response and oncological prognosis.
    Transl Androl Urol. 2019;8.
    PubMed     Text format    
    
    
28. AGARWAL A, Sonpavde G
    A new subtyping model for residual invasive disease after cisplatin-based neoadjuvant chemotherapy for muscle invasive bladder cancer.
    Transl Androl Urol. 2019;8.
    PubMed     Text format    
    
    
29. TODENHOFER T, Seiler R
    Molecular subtypes and response to immunotherapy in bladder cancer patients.
    Transl Androl Urol. 2019;8.
    PubMed     Text format    
    
    
30. NIEGISCH G
    Should we spare neoadjuvant chemotherapy in low-risk muscle-invasive bladder cancer patients scheduled for radical cystectomy?
    Transl Androl Urol. 2019;8.
    PubMed     Text format    
    
    
31. AFFERI L, Zamboni S, Baumeister P, Mordasini L, et al
    Adjuvant chemotherapy in bladder cancer patients with histological variants: time to change the approach?
    Transl Androl Urol. 2019;8.
    PubMed     Text format    
    
    
32. MAAS M, Stenzl A
    Should every patient with muscle-invasive bladder cancer receive neoadjuvant chemotherapy?
    Transl Androl Urol. 2019;8.
    PubMed     Text format    
    
    

    
    Turk Patoloji Derg

33. BOYACI C, Behzatoglu K
    Diagnostic Value of Glucose Transporter 1 (GLUT-1) Expression in Nested Variant of Urothelial Carcinoma.
    Turk Patoloji Derg. 2019;35:22-27.
    PubMed     Text format     Abstract available
    
    

    
    Urol Oncol

34. BORKOWSKA EM, Traczyk-Borszynska M, Kutwin P, Pietrusinski M, et al
    Usefulness of droplet digital PCR and Sanger sequencing for detection of FGFR3 mutation in bladder cancer.
    Urol Oncol. 2019 Jul 31. pii: S1078-1439(19)30239.
    PubMed     Text format     Abstract available
    
    
35. ZHANG J, Zhu Y, Wang Q, Kong Y, et al
    Poliovirus receptor CD155 is up-regulated in muscle-invasive bladder cancer and predicts poor prognosis.
    Urol Oncol. 2019 Aug 2. pii: S1078-1439(19)30282.
    PubMed     Text format     Abstract available
    
    
36. SEILER R, Black PC, Williams SB, Goebell PJ, et al
    Editorial: Bladder cancer within the focus of basic and clinical research. Sixth IBCN Seminars Series.
    Urol Oncol. 2019 Jul 31. pii: S1078-1439(19)30254.
    PubMed     Text format    
    
    

    
    World J Urol

37. DAVARO F, Schaefer J, May A, Raza J, et al
    Invasive non-urachal adenocarcinoma of the bladder: analysis of the National Cancer Database.
    World J Urol. 2019;37:497-505.
    PubMed     Text format     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Bladder Cancer is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: